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At present there is considerable activity in the area of preven- 
tion of atherosclerosis-related events using angiotensin- 
converting enzyme inhibitors. Large trials have demonstrated 
significant reductions in cardiovascular morbidity and mortality 
with long-term use of angiotensin-converting enzyme inhibitors in 
patients with left ventricnlar dysfunction, heart failure or acute 
myocardial infarction. Reductions in acute ischemic events (e.g., 
myocardial infarction, unstable angina and need for early revas- 
cularization) were independent of ejection fraction and were 
greater than would be expected from the small reduction in blood 
pressure that occurred, suggesting that other patients with coro- 
nary artery disease may benefit from angiotensin-converting 
enzyme inhibitor therapy. This hypothesis i  being tested in multiple 
double-blind, randomized, controlled clinical trials with durations of 
follow-up of 3 to 5 years that will involve approximately 30,000 
patients. The trials vary with respect to patient population (e.g., 
normotensive vs. hypertensive, normolipidemic vs. hyperlipidemic, 
with vs. without diabetes mellitus), angiotensin-converting enzyme 
inhibitor used and outcome measures. When available, the results of 
these clinical trials could have very important implications for the 
role of long-term angiotensin-converting enzyme inhibitor therapy 
for preventing or delaying the development of atherosderosis-related 
ischemic events. 
(JAm CoU Cardiol 1996;27:1048-52) 
Angiotensin-converting enzyme inhibitors possess many im- 
portant properties in addition to the antihypertensive effects 
for which they were introduced. These other properties are 
potentially of greater importance in terms of preventing or 
delaying the development of atherosclerosis-related adverse 
outcomes (1). 
Animal and human studies have demonstrated that 
angiotensin-converting e zyme inhibitors exhibit cardioprotec- 
tive and vasculoprotective properties. Mechanisms for their 
vasculoprotective properties include, in addition to inhibition 
of angiotensin II generation and bradykinin degradation, an- 
tagonism of macrophage function and migration as well as 
inhibition of sympathetic nervous ystem and thrombotic ac- 
tivity. All of these could lead to plaque stabilization, protec- 
tion against plaque rupture and prevention of acute coronary 
occlusion, which is responsible for most coronary artery 
disease-related a verse outcomes (2). 
The Studies of Left Ventricular Dysfunction (SOLVD) (1) 
and the Survival and Ventricular Enlargement (SAVE) trials 
showed that long-term use of angiotensin-converting enzyme 
inhibitors in patients with left ventricular dysfunction (ejection 
fraction -<40%) after myocardial infarction significantly reduces 
cardiovascular morbidity and mortality (1,3,4). Important coro- 
nary artery disease-related outcomes of these trials included 
reductions by -24% in the risk of recurrent myocardial infarction 
and need for revascularization a d a reduction i  the likelihood of 
hospital admission for unstable angina (1,3,4). 
Although the effects of angiotensin-converting e zyme in- 
hibitors in patients with preserved left ventricular function 
(ejection fraction >40%) are unknown, findings from the 
SOLVD and SAVE trials suggest that benefits are likely (1-4). 
This is because the magnitude of the reductions in the occur- 
rence of acute coronary artery disease-related vents were 
independent of ejection fraction, background cardiac medica- 
tions and comorbid factors uch as diabetes mellitus and prior 
revascularization, and they were greater than would be ex- 
pected from the mild reduction in blood pressure that occurred 
(1,3,4). In addition, the magnitude of coronary artery disease- 
related risk reduction observed and duration of therapy re- 
quired for emergence ofbenefits (>6 months) were similar (1). 
These findings uggest that the benefit of long-term angiotensin- 
converting enzyme inhibitor therapy is likely to extend to a 
broader population of patients with coronary artery disease 
than those treated in the SOLVD, SAVE and other postmyo- 
cardial infarction trials. 
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Ongo ing  C l in ica l  T r ia l s  
At least eight randomized, multicenter clinical trials in 
progress are assessing the effect of long-term angiotensin- 
converting enzyme inhibitor therapy in patients with coronary 
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Table 1. Clinical Outcome Studies of Angiotensin-Converting Enzyme Inhibitor Treatment in Patients With Coronary Artery Disease and 
Preserved Left Ventricular Function: Summary of Design Characteristics 
Study/Principal Duration of Projected 
Investigator(s) Design ACE Inhibitor Follow-Up Sample Size Age (yr) 
Inclusion Criteria 
Other Primary Outcome 
QUIET R, DB, PC Quinapril, 3 yr 1,742 
B. Pitt 20 mg/d 
R. Lees 
HOPE R, DB, PC Ramipril, <4 yr 9,541 
S. Yusuf 2 x 2 factorial 10 mg/d 
T. Montague ('+vitamin E 
P. Sleight 400 IU/d) 
Canadian 
Collaboration 
ALLHAT R, DB, C Lisinopril 
J. Wright 10-40 mg/d 
(_+pravastatin 
20-40 mg/d) 
PEACE R, DB, PC Trandolapril 
M. Dnmanski, 4 mg/d 
M. Pfeffer 
18-75 1- or 2-vessel CAD, Cardiac ischemic 
PTCA/atherectomy events (CV death, nonfatal 
within 72 h, controlled MI, revascularization, 
hypertension, LDL < 165 unstable angina); CAD 
mg/dl progression by QCA 
->55 High risk for major CV CVD events: MI, stroke, CV 
event death 
6 yr (mean) 4,230* ->55 Hypertension, CV death, nonfatal MI, fatal 
atherosclerotic CV MI; all-cause mortality 
disease, type II 
diabetes mellitus, 
HDL < 35 mg/dl, 
LVH, smoking, 55% 
blacks 
5 yr 14,000 ->50 Documented CV death, MI 
CAD 
*Sample size given is for the lisinopril arm in each trial. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) consists of two 
practice-based trials: an antihypertensive trial (20,000 patients) with four arms comparing lisinopril, chlorthalidone, doxazosin and amlodipine; and a cholesterol-lowering trial 
(20,000 patients) comparing a cholesterol-lowering diet plus pravastatin added to antihypertensive tr atment or cholesterol-lowering diet plus usual care (antihypertensive 
treatment alone). ACE = angiotensin-converting e zyme; C = controlled; CAD = coronary artery disease; CV(D) = cardiovascular (disease); d = day; DB - double-blind; 
HDL = high density lipoprotein; HOPE = Heart Outcomes Prevention Evaluation; LDL - low density lipoprotein; LVH = left ventricular hypertrophy; MI = myocardial 
infarction; NHLBI = National Heart, Lung and Blood Institute; PC = placebo-controlled; PEACE = Prevention of Events With Angiotensin-Converting Enzyme Inhibition; 
PTCA = percutaneous transluminal coronary angioplasty; QCA - quantitative coronary angiography; QUIET = Quinapril Ischemic Event Trial; R = randomized. 
artery disease and preserved left ventricular function. Tables 1 
and 2 summarize the pertinent characteristics of these trials, 
which are listed in order of dates when study results are 
expected to be available. Various angiotensin-converting en- 
zyme inhibitors and outcome measures of atherosclerosis are 
being studied, and there are differences in patient populations 
Table 2. Surrogate Outcome Studies of Angiotensin-Converting Enzyme Inhibitor Treatment in Patients With Coronary Artery Disease and 
Preserved Left Ventricular Function: Summary of Design Characteristics 
Inclusion Criteria 
Study/Principal Duration of Projected 
Investigator(s) Design ACE Inhibitor Follow-Up Sample Size Age (yr) Other Primary Outcome 
TREND R, DB, PC Qulnapril 6 mo 129 18-75 
G. Mancini 40 mg/d 
SECURE R, DB, PC Ramipril 3-4 yr 732 ->55 
E. Lonn 3 × 2 factorial 2.5 and 
S. Yusuf 10 mgc'd 
(_+vitamin E 
400 1U/d) 
PART-2 R, DB, PC Ramipril 4 yr 600 18-75 
N. Sharpe 5-10 mg/d 
S. MacMahon 
SCAT R, DB, PC Enalapril 5 yr 468 NA 
K. Ten 2 x 2 factorial (_+simvastatin) 
T. Montague 
1- or 2-vessel CAD, Endothelium-dependent 
controlled vasoconstriction assessed 
hypertension, LDL by response to ACh and 
< 165 mg/dl measured by QCA 
High risk for major B-mode ultrasound 
CV event measures of carotid 
atherosclerosis 
Clinically important B-mode ultrasound 
atherothrombotic measures of carotid 
disease within 5 yr atherosclerosis 
Documented CAD, total CAD progression 
cholesterol 160-240 by QCA 
mg/dl 
ACh = acetylcholine; NA = not available; PART = Prevention of Atherosclerosis With Ramipril Therapy; SCAT = Simvastatin Coronary Atheroselerosis Trial; 
SECURE = Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E; TREND = Trial on Reversing Endothelial Dysfunction; 
other abbreviations a in Table 1. 
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(e.g., normotensive or controlled vs. hypertensive, normolipi- 
demic vs. hyperlipidemic, with vs. without diabetes mellitus). 
In three trials, other therapeutic agents in combination with an 
angiotensin-converting enzyme inhibitor are being evaluated 
for their effect on coronary artery disease. 
Clinical outcome trials. Four trials are evaluating the effect 
of angiotensin-converting enzyme inhibition on clinical out- 
come measures related to coronary artery disease--death, 
myocardial infarction, unstable angina and need for revascu- 
larization. Results of these trials are likely to provide informa- 
tion important for clinical decision making. 
Quinapril Ischemic Event Trial (QUIET). The QUIET 
study (5,6) was initiated in 1991 to assess the antiatheroscle- 
rotic effect of long-term angiotensin-converting e zyme inhi- 
bition in normotensive orcontrolled hypertensive patients with 
average lipid levels and coronary atherosclerosis without left 
ventricular dysfunction (Table 1). The hypothesis being tested 
is that angiotensin-converting enzyme inhibitors reduce the 
rate of cardiac ischemic events and delay or prevent the 
development of coronary artery atherosclerosis (5,6). Initial 
results are expected in late 1996. 
In this multinational trial, patients were randomized to 
quinapril (20 mg/day) or placebo within 12 to 72 h after 
successful angioplasty or atherectomy and are being followed 
up for 36 months (5,6). In addition to the clinical outcomes 
given in Table 1, secondary response variables, evaluated in a 
randomly selected subpopulation (-30% of patients), include 
progression or lack of progression/regression of coronary 
artery disease assessed by quantitative coronary angiography. 
In a substudy, angiotensin-converting enzyme gene poly- 
morphism will be determined in all patients. Some investiga- 
tors have reported (7) that a variant of the angiotensin- 
converting enzyme gene (a deletion within intron 16) 
associated with higher levels of circulating angiotensin- 
converting enzyme appears to increase the risk of myocardial 
infarction in the absence of other cardiovascular risk factors. The 
objective of the substudy is to examine the frequency of the 
deletion polymorphism in the gene encoding angiotensin- 
converting enzyme with coronary artery disease-related vents. 
The substudy will also determine if angiotensin-converting en-
zyme genotyping can characterize patients at risk for progression 
of atherosclerosis and identify those who are more likely to 
benefit from angiotensin-converting e zyme inhibitor therapy. 
Another substudy will use intravascular coronary ultra- 
sound to examine arterial wall changes to determine whether 
there are differences in the atherosclerotic process in quinapril- 
and placebo-treated patients and whether estenosis develops in 
intervened vessels. Patients will undergo ultrasound and coronary 
angiography at baseline, 6 months and 36 months. 
Because angiotensin-converting enzyme inhibitors reduce 
insulin resistance and improve insulin sensitivity in patients 
with non-insulin-dependent diabetes mellitus and in nondia- 
betic patients (8), a substudy will assess whether increased 
insulin sensitivity induced by quinapril correlates with a reduc- 
tion in cardiac ischemic events compared with placebo. Serum 
glucose and insulin levels will be measured at baseline, 2 
months and 36 months in the 1,300 patients enrolled at North 
American centers. 
Heart Outcomes Prevention Evaluation (HOPE). The 
HOPE trial is evaluating the effects of ramipril (titrated to 
10 mg/day) and vitamin E (400 IU/day) on atherosclerosis in a 
2 x 2 factorial design. As of January 1, 1996 the study 
completed randomizing 9,541 patients. This included 2,543 
women, 7,553 patients with cardiovascular disease and 3,654 
with diabetes. All patients are ->55 years old and about one 
half are >65. There are 267 centers worldwide. The rationale 
for the use of vitamin E is that it inhibits formation of oxidized 
low-density lipoprotein, which is highly atherogenic (9). Anti- 
oxidants may, therefore, retard atherosclerosis or its clinical 
sequelae. The range of high-risk patients in the trial is broad 
(e.g., coronary disease, peripheral vascular disease, previous 
stroke, diabetes mellitus [insulin-dependent and non- 
insulin-dependent]). Two groups of patients with diabetes are 
included--those with a history of cerebrovascular disease and 
those without who have at least one other cardiac risk factor. 
In addition to the primary clinical outcome measures shown in 
Table 1, secondary end points include the number of hospi- 
talizations for unstable angina, emergent revascularization 
procedures, development of congestive heart failure (for 
ramipril), cardiovascular mortality, total mortality and ne- 
phropathy (patients with diabetes). 
Substudies include one to assess left ventricular mass, 
function and arrhythmic activity by two-dimensional quantita- 
tive echocardiography and ambulatory ECG monitoring; an- 
other to assess risk factors for atherosclerosis u ing a nested 
case-control study design; and one to assess renal function and 
microalbuminuria. Other anticipated substudies are as- 
sessments of neurohormonal ctivity (renin, angiotensin II, 
angiotensin-converting e zyme) by conventional ssay meth- 
ods, vitamin E levels using deuterium-labeled mass spectrom- 
etry, and functional capacity in patients with peripheral car- 
diovascular disease. 
Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial (ALLHAT). The ALLHAT study consists of 
two large practice-based, randomized trials with eligibility 
criteria defined so as to select high risk hypertensive patients 
without he need for extensive diagnostic testing (Table 1). In 
the antihypertensive trial, the effects of four agents (chlortha- 
lidone, amlodipine, doxazosin and lisinopril) on the combined 
incidence of fatal coronary heart disease and nonfatal myocardial 
infarction are being compared (10). In the cholesterol-lowering 
trial, patients with hypertension and moderate hypercholesterol- 
emia are randomized to receive a cholesterol-lowering diet and 
either the 3-hydroxymethylglutaryl coenzyme A reductase inhib- 
itor pravastatin or usual care (plus one of the four antihyperten- 
sive agents) to determine whether pravastatin reduces all-cause 
mortality compared with usual care. A total of 40,000 patients are 
to be enrolled in the hypertension trial, 20,000 of whom will 
participate in the cholesterol-lowering trial. 
Secondary objectives of both trials include a comparison of 
the effects of the respective treatment regimens on cardiovas- 
cular mortality, major morbidity, health costs and health- 
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related quality of life. For the antihypertensive trial, secondary 
objectives are a comparison of the effects of the different 
treatments on all-canse mortality and major hypertension- 
related morbidity (incidence and regression of left ventricular 
hypertrophy, progressive r nal dysfunction). For the cholesterol- 
lowering trial, secondary objectives are to determine the 
long-term safety of pravastatin older patients and the effect 
of lipid lowering on cancer incidence and mortality and on the 
combined incidence of fatal coronary heart disease and non- 
fatal myocardial infarction. 
Prevention of Events With Angiotensin-Converting E zyme 
Inhibition (PEACE). The primary objective of the PEACE 
trial, which is targeted to begin in 1996, is to determine 
whether addition of angiotensin-converting e zyme inhibitor 
therapy (trandolapril, titrated to 4 mg/day) to standard therapy 
in patients with coronary artery disease and preserved left 
ventricular function prevents cardiovascular mortality and 
reduces the risk of myocardial infarction (11) (Table 1). A 
secondary objective is to determine whether long-term 
angiotensin-converting e zyme inhibition reduces cardiovascu- 
lar death and hospital admissions for primary cardiovascular 
complications--myocardial infarction, unstable angina, revas- 
cularization, cerebral vascular events, congestive heart failure 
or arrhythmias. Smaller mechanistic-type substudies to eluci- 
date molecular genetics are planned. 
Surrogate nd-point trials. Four trials are assessing surro- 
gate outcome measures of carotid or coronary atherosclerosis-- 
endothelial dysfunction assessed by response to intracoronary 
acetylcholine challenge, B-mode ultrasound and progression of 
coronary artery disease assessed by quantitative coronary 
angiography. These trials will provide insight regarding the 
mechanisms by which angiotensin-converting enzyme inhibi- 
tors exert their antiatherogenic effects. 
Trial on Reversing Endothelial Dysfunction (TREND). The 
objective of TREND, a parallel study to QUIET, is to deter- 
mine the effect of quinapril (titrated to 40 mg daily) on a 
postulated early manifestation of atherosclerosis, endothelial 
dysfunction (12), in 129 patients undergoing coronary revascu- 
larization (Table 2). Eligible patients had one main coronary 
artery with <40% stenosis and no history of coronary artery 
spasm, and the target artery had to demonstrate an abnormal 
response (vasoconstriction or no dilation) to acetylcholine. 
Endothelium-dependent vasoconstriction was assessed by se- 
rial intracoronary acetylcholine infusions followed by quanti- 
tative coronary angiography at baseline and 6 months. Lumen 
diameter changes in the target vessel and the effect of quinapril 
on coronary endothelial reactivity were determined by angiog- 
raphy. In a substudy of TREND, Doppler measures of coro- 
nary blood flow velocity were made to assess microvascular 
endothelial function and coronary flow reserves in response to 
acetycholine and the direct-acting vasodilator adenosine. This 
trial has been completed and is in the data analysis phase. 
Study to Evaluate Carotid Ultrasound Changes in Patients 
Treated With Ramipril and Vitamin E (SECURE). SECURE is 
a complementary substudy of the HOPE trial utilizing a 
surrogate outcome measure--B-mode ultrasound measure- 
ments of the change in carotid arterial wall thickness (Table 
2)--to provide insight into the mechanisms by which ramipril 
(10 and 2.5 rag/day) and vitamin E (400 IU/day) affect he rate 
of progression of carotid atherosclerosis in patients at high risk 
for cardiovascular events. Quantitative ultrasound will be 
performed at baseline and yearly for 4 years. The individual 
regression slope in the mean of maximal intimal-medial thick- 
ness over time, averaged from measurements at 12 preselected 
carotid artery segments, is the primary outcome measure. 
Other outcome measures include the regression slope for each 
patient of the single maximal intimal-medial thickness among 
the preselected segments, which is considered the most impor- 
tant lesion hemodynamically, and new plaque formation, which 
will be determined by comparing serial ultrasound studies. 
Prevention of Atheroselerotic Risk and Thrombosis (PART-2). 
The primary objectives of the PART-2 trial are to assess 
whether amipril (5 to 10 rag/day) slows progression of athero- 
sclerosis in carotid arteries and reduces left ventricular mass in 
patients with a history of coronary disease, transient cerebral 
ischemia, or peripheral vascular disease (Table 2). Thickness 
of the far walls of the right and left common carotid arteries is 
measured by B-mode ultrasound, and M-mode ultrasound 
scans are done to measure left ventricular dimensions at 
baseline and at 2 and 4 years. Clinical outcomes being monitored 
are hospital admissions, nonfatal cardiovascular nd other clinical 
events, and cardiovascular nd noncardiovascular deaths. 
Patients for the PART-2 trial are being drawn from the 
Predictors of Atherosclerotic Risk and Thrombosis (PART-l) 
study, a case-control study of the causes of clinically manifest 
atherothrombotic disease. Approximately 750 patients with 
coronary heart disease, transient cerebral ischemia, or periph- 
eral vascular disease will be screened for PART-1 (those who 
meet he entry criteria are enrolled in PART-2) with age- and 
sex-matched controls selected randomly from general practice 
sites. Lipids and lipoproteins, red blood cell membrane fatty 
acids, antioxidants, oxidatively modified particles, hemostatic 
factors, blood pressure, heart rate and anthropometric variables 
will be measured, and information on diet and life-style collected 
to determine the relation of various factors to the overall risk of 
atherothrombotic disease and whether there are differences inthe 
magnitude of the relationship with coronary heart disease, cere- 
brovascular disease and peripheral vascular disease. 
Simvastatin Coronary Atherosclerosis Trial (SCAT). Al- 
though most patients with coronary artery disease have cho- 
lesterol levels either within or slightly above normal imits, it is 
unclear whether cholesterol-lowering therapy (e.g., simvasta- 
tin) will produce regression in these patients. Other mecha- 
nisms (e.g., cellular proliferation in the arterial wall) are 
important in the pathogenesis of atherosclerosis, suggesting 
that other therapies (e.g., angiotensin-converting e zyme in- 
hibitors) may be useful. These findings provide the rationale 
for SCAT, which is evaluating whether dietary intervention 
along with treatment with enalapril or simvastatin, or both, will 
promote regression or decrease progression of coronary ath- 
erosclerosis n patients with normal or mildly elevated choles- 
terol levels (Table 2). The extent of atherosclerosis will be 
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measured anatomically by quantitative coronary angiography 
performed at baseline and after 5 years and functionally by 
body surface potential mapping performed at one center at 
baseline, 2.5 years and 5 years. Clinical and laboratory evalu- 
ations and plasma lipid determinations are being performed at 
regular intervals. 
Imp l i ca t ions  o f  Resu l ts  F rom C l in ica l  T r ia l s  
Findings from these clinical trials will expand the current 
knowledge of the role of angiotensin-converting enzyme inhi- 
bition in the pathophysiology as well as management of 
coronary artery disease. Those trials with surrogate outcome 
measures may elucidate further the mechanism(s) by which 
angiotensin-converting enzyme inhibitors produce their bene- 
ficial effects. The results of the clinical outcome trials may 
extend the findings of the SOLVD and SAVE trials, which first 
showed significant reductions in atherosclerosis-related mor- 
bidity and mortality, to patients with coronary artery disease 
and preserved left ventricular function treated long-term with 
an angiotensin-converting enzyme inhibitor. Moreover, the 
trials will provide insight into the role of therapy with 
angiotensin-converting enzyme inhibitors and other pharma- 
cologic agents (e.g., cholesterol-lowering agents, antioxidants) 
affecting the pathogenesis of atherosclerosis, either alone or i n 
combination. Perhaps these findings will impact on the large 
number of patients with coronary artery disease who might 
otherwise have died before medical attention was received or 
survived with acute myocardial infarction as their initial event. 
Thus, the results of these trials could have important public 
health implications. 
We gratefully acknowledge the assistance of those investigators who shared 
information about the trials: Barry Davis, MD, PHD, [ALLHAT]; Michael J. 
Domanski, MD, [PEACE]; Koon K. Teo, MD, [SCAT]; Marc A. Pfeffer, MD, 
PuD, [PEACE]; Bertram Pitt, MD, [QUIET]; Norman Sharpe, MD, [PART]; 
and Salim Yusuf, DPhil, ]HOPE/SECURE]. 
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